Drugs / APG-2575
Trials 33 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT03537482 | Aug 2018 → Sep 2024 overdue | hematopoietic and lymphoid cell neoplasm | Ascentage Pharma Group Inc. | Recruiting | No outcome recorded |
| Phase 17 trials | ||||||
| Phase 1 | NCT07428486 | Apr 2026 | T lymphoblastic leukemia/lymphoma | M.D. Anderson Cancer Center | Withdrawn | No outcome recorded |
| Phase 1 | NCT05701306 | Feb 2023 → Jun 2026 overdue | neuroblastoma | Ascentage Pharma Group Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT05517616 | Sep → Nov 2022 | — | Ascentage Pharma Group Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05495035 | Sep 2022 → Aug 2024 | B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2), childhood acute lymphoblastic leukemia | Institute of Hematology & Blood Diseases Hospital, China | Unknown | No outcome recorded |
| Phase 1 | NCT04260217 | May 2021 → Feb 2024 | Waldenstrom macroglobulinemia | Ascentage Pharma Group Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04215809 | Mar 2020 → Oct 2025 overdue | chronic lymphocytic leukemia/small lymphocytic lymphoma | Ascentage Pharma Group Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT03913949 | Jun 2019 → Oct 2024 overdue | B-cell chronic lymphocytic leukemia | Ascentage Pharma Group Inc. | Active not recruiting | No outcome recorded |
| Phase 1/210 trials | ||||||
| Phase 1/2 | NCT07601607 | May 2026 → May 2028 expected | relapsed/refractory diffuse large B-cell lymphoma | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07398638 | Feb 2026 → Feb 2029 expected | diffuse large B-cell lymphoma | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07159906 | Sep 2025 → Aug 2027 expected | diffuse large B-cell lymphoma | First Affiliated Hospital of Zhejiang University | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06182969 | Aug 2024 → Apr 2026 overdue | systemic lupus erythematosus | Ascentage Pharma Group Inc. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04942067 | Dec 2021 → Sep 2024 | amyloidosis, plasma cell myeloma | Ascentage Pharma Group Inc. | Unknown | No outcome recorded |
| Phase 1/2 | NCT04946864 | Aug 2021 → Aug 2024 | breast cancer | Ascentage Pharma Group Inc. | Suspended | No outcome recorded |
| Phase 1/2 | NCT04964518 | Jul 2021 → Jul 2024 | acute myeloid leukemia | Ascentage Pharma Group Inc. | Unknown | No outcome recorded |
| Phase 1/2 | NCT04674514 | Apr 2021 → Jan 2024 | plasma cell myeloma | Ascentage Pharma Group Inc. | Unknown | No outcome recorded |
| Phase 1/2 | NCT04501120 | Sep 2020 → Sep 2028 expected | acute myeloid leukemia | Ascentage Pharma Group Inc. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04494503 | Aug 2020 → Oct 2024 overdue | chronic lymphocytic leukemia/small lymphocytic lymphoma | Ascentage Pharma Group Inc. | Recruiting | No outcome recorded |
| Phase 28 trials | ||||||
| Phase 2 | NCT07684950 | Jun 2026 → Oct 2028 expected | mantle cell lymphoma | Henan Cancer Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07602322 | May 2026 → May 2028 expected | large B-cell lymphoma | Ruijin Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07552324 | May 2026 → May 2027 expected | T-cell/histiocyte rich large B cell lymphoma | Ruijin Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07459608 | Mar 2026 → Jan 2027 expected | chronic lymphocytic leukemia/small lymphocytic lymphoma, marginal zone lymphoma | Henan Cancer Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07255963 | Nov 2025 → Sep 2028 expected | diffuse large B-cell lymphoma | The First Affiliated Hospital of Soochow University | Recruiting | No outcome recorded |
| Phase 2 | NCT07272499 | Sep 2025 → Sep 2028 expected | mantle cell lymphoma | Ruijin Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT05147467 | Dec 2021 → Dec 2026 expected | chronic lymphocytic leukemia/small lymphocytic lymphoma | Ascentage Pharma Group Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT04496349 | Jul 2021 → May 2026 overdue | T-cell prolymphocytic leukemia | Ascentage Pharma Group Inc. | Recruiting | No outcome recorded |
| Phase 2/33 trials | ||||||
| Phase 2/3 | NCT07597941 | Jul 2026 → Jun 2028 expected | acute promyelocytic leukemia | The Affiliated People's Hospital of Ningbo University | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT07651163 | Mar 2026 → Dec 2029 expected | acute myeloid leukemia | First Affiliated Hospital of Zhejiang University | Enrolling by invitation | No outcome recorded |
| Phase 2/3 | NCT07651176 | Mar 2026 → Dec 2029 expected | acute myeloid leukemia | First Affiliated Hospital of Zhejiang University | Enrolling by invitation | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT07686965 | Aug 2026 → Aug 2030 expected | acute myeloid leukemia | Institute of Hematology & Blood Diseases Hospital, China | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06641414 | Jan 2025 → Jun 2029 expected | myelodysplastic syndrome | Ascentage Pharma Group Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT06389292 | Jun 2024 → May 2028 expected | acute myeloid leukemia | Ascentage Pharma Group Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT06319456 | Apr 2024 → Aug 2027 expected | chronic lymphocytic leukemia/small lymphocytic lymphoma | Ascentage Pharma Group Inc. | Recruiting | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06104566 Comparator | Dec 2023 → Dec 2026 expected | chronic lymphocytic leukemia/small lymphocytic lymphoma | Ascentage Pharma Group Inc. | Recruiting | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 35 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | APG-2575 | “A Global Multicenter, Open Label, Randomized Phase 3 Registrational Study of Lisaftoclax (APG-2575) in Previously Treated Patients With Chronic Lymphocytic Leukemia/Small...” NCT06104566 ↗23“Phase Ib/II study of safety, tolerability, efficacy and PK of APG-2575 as a single agent or in combination with other therapeutic agents including ibrutinib or rituximab.” NCT04260217 ↗ “Safety, tolerability, and pharmacokinetics of lisaftoclax (APG-2575)-based therapy in patients with chronic lymphocytic leukemia: Phase 1b/2 study.” PMID 41109219 ↗ Oct 2025 “Lisaftoclax (APG-2575) is given for DS prophylaxis in patients with peripheral WBC count \>2.0×10⁹/L or ≥24-hour 2-fold WBC elevation.” NCT07597941 ↗ “Lisaftoclax (APG-2575) orally once daily, every 28 days as a cycle.” NCT04501120 ↗ “lisaftoclax (APG-2575), an oral selective BCL-2 inhibitor” NCT07459608 ↗ “Drug: Lisaftoclax (APG-2575)” NCT07272499 ↗ “Lisaftoclax (APG-2575)” NCT06319456 ↗ “Lisaftoclax (APG-2575)” NCT06641414 ↗ |
| Known as | [14C] APG-2575 | “A Single-center, Open-label, Single-dose Phase 1 Clinical Study to Investigate the Absorption, Metabolism and Excretion of APG-2575 in Healthy Subjects After Oral...” NCT05517616 ↗ |
| Known as | Lisaftoclax | “R 375 mg/m2 D1 Pola 1.8mg/kg D1 CTX 750mg/m2 D2 ADR 50mg/m2 D2 Pred 60 mg/m2 D2-6 Chidamide 20mg/d D1,4,8,11 Lisaftoclax 600mg/d D1-21” NCT07552324 ↗19“Venetoclax (or Lisaftoclax, depending on study drug) is a selective oral BCL-2 inhibitor that restores apoptosis in tumor cells.” NCT07159906 ↗ “GC Type: Glofitamab + BCL-2 inhibitor (e.g., Lisaftoclax/Venetoclax)” NCT07602322 ↗ “APG-2575(Lisaftoclax )” NCT06389292 ↗ |
| Action | Inhibit | “Lisaftoclax is a selective, small-molecule oral BCL-2 inhibitor.” PMID 41109219 ↗ Oct 2025 |
| Modality | Small molecule | “Lisaftoclax is a selective, small-molecule oral BCL-2 inhibitor.” PMID 41109219 ↗ Oct 2025 |
| Route | Oral | “APG-2575 will be administered as an oral tablet” NCT03537482 ↗ |
| Target | BCL2 | “Lisaftoclax is a selective, small-molecule oral BCL-2 inhibitor.” PMID 41109219 ↗ Oct 2025 |